The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

Br J Cancer · 2012 · PMC3251866 · PMID 22134511

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP =0.08so close (0.05 < p ≤ 0.1)

Exploratory landmark analysis of CA19-9 showed a trend towards shorter PFS for patients with higher CA19-9 levels 6 weeks after commencing treatment (HR 1.8; 95% CI 0.94–3.71; P =0.08).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.